In the news
View the latest updates from the 59 North team and our clients below:
20
Mar
2026
KMA and LMA antigens emerge as high value targets for plasma cell dyscrasia treatment
18
Mar
2026
Cereno Scientific Receives Approval to Initiate Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD
18
Mar
2026
One-carbon Therapeutics Signs Collaboration with Tempus to Advance Molecular Insights and Enable Precision Oncology Development of TH9619
13
Mar
2026
Targeting What Others Miss: How HaemaLogiX Is Tackling Multiple Myeloma’s Toughest Challenges
HaemaLogiX has been in the spotlight as it advances a differentiated approach to multiple myeloma, the world’s second‑largest blood cancer. In a recent episode of ...